menu ☰
menu ˟

[Comment] Kinase inhibition in rheumatoid arthritis: a big advance?

09 Feb 2013

Treatment of rheumatoid arthritis is an active and competitive field. Key milestones have been the extended use of methotrexate since 1980, and introduction of the first biotherapy targeting tumour necrosis factor (TNF) in 2000. There are currently five TNF inhibitors on the market, as well as biotherapies that target B cells and T-cell interactions. This progress comes from the development of monoclonal antibodies, fusion proteins of soluble receptors, and inhibitors. These protein therapeutics are administered systemically, either intravenously or subcutaneously, on a weekly or monthly basis.

Date: 
9 February 2013

Click here to view the full article which appeared in The Lancet